Prophylaxis and treatment of coronavirus infection
AssigneesLudwig ENGLMEIER, Bourgelat Pty Ltd
InventorLudwig ENGLMEIER
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of antagonists of tlr7-signalling for the treatment of COVID-19 patients, wherein the antagonists of tlr7-signalling are administered only after serovonversion. The invention also relates to a tlr agonist for use in the one-time prophylactic treatment of a subpopulation against an infection with a coronavirus, wherein the subpopulation is a collection of asymptomatic subjects in proximity to subjects of the population who show symptoms of infection.
Claims21
-28. (canceled)
An antagonist of tlr7-signalling for use in the treatment of COVID-19, wherein the antagonist of tlr7-signalling is to be administered after seroconversion.
A tlr agonist for use in the one-time prophylactic treatment of a subpopulation against an infection with a coronavirus, wherein the subpopulation is a collection of asymptomatic subjects in proximity to subjects of the population who show symptoms of infection.
A tlr agonist for use in the prophylactic treatment of asymptomatic subjects against an infection with a coronavirus in an emergency situation.
Dependencies are inferred from the claim text.